Zynex, Inc. to Announce First Quarter 2022 Financial Results
Zynex, a medical technology company, will release its first quarter 2022 financial results on April 28, 2022. The conference call and webcast will be held at 4:15 p.m. ET to discuss the results and provide a corporate update. Zynex specializes in non-invasive medical devices for pain management and patient monitoring. For further details on the event, interested parties can register through a provided link.
- Upcoming conference call to discuss financial results may indicate transparency and engagement with investors.
- No specific financial metrics or guidance provided, leaving investors without critical data to assess performance.
ENGLEWOOD, Colo., April 18, 2022 /PRNewswire/ -- April 18, 2022 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2022 financial results on Thursday, April 28, 2022. Zynex's management will host a conference call and webcast at 4:15 p.m. ET that day to discuss the financial results and provide a corporate update.
Webcast Details: Thursday, April 28, 2022 at 2:15 p.m. MT / 4:15 p.m. ET
To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast: https://app.webinar.net/XNl5a6za9R8
US Participant Dial In (TOLL FREE): 1-844-825-9790
International Participant Dial In: 1-412-317-5170
Canada Participant Dial In (TOLL FREE): 1-855-669-9657
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation as well as developing noninvasive patient fluid, pulse oximetry and sepsis monitoring systems. For additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2021 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-inc-to-announce-first-quarter-2022-financial-results-301526929.html
SOURCE Zynex
FAQ
What date will Zynex report its first quarter 2022 financial results?
What time is the conference call for Zynex's financial results?
How can I participate in Zynex's webcast?
